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Summary
WHO first recognised extranodal NK/T-cell lymphoma 
(ENKTCL) in 2001, thanks to technical advances in 
anatomopathology and immunohistochemistry. It is 
divided into nasal and extranasal subgroups depending 
on the primary site. Primary isolated NK/T-cell lymphoma 
of the testis is rare. Typical recurrence sites of primary 
testicular NK/T-cell lymphoma are the gastrointestinal 
tract, lymph nodes, skin, spleen and central nervous 
system. Nasal relapses of a primary NK/T-cell lymphoma 
of the testis are very rare and according to our 
knowledge, no other case has been reported yet in the 
literature. The authors report the case of a 35-year-
old Caucasian man relapsing twice in the nasal cavity 
1 year after initial diagnosis and treatment of a primary 
isolated, stage IE, ENKTCL of the testis. We report 
the clinical and radiological presentation of the nasal 
relapses and the different modalities of treatment that 
were applied. Sinonasal relapses of an isolated primary 
NK/T-cell lymphoma of the testis are very rare. ENKTCL is 
a very aggressive entity, even at an early stage, therefore, 
requiring a multimodal treatment approach including 
chemotherapy and radiotherapy. New strategies to treat 
this disease are needed.
BaCkground
Natural Killer (NK)/T-cell lymphoma represents less 
than 5% of all lymphomas. It comes from NK cells, 
cytolytic lymphocytes of the innate immune system, 
responsible for immune responses to bacterial and 
viral infections. It is almost always (>95%) asso-
ciated with the Epstein-Barr virus (EBV),1 which 
plays an important role in the lymphomagenesis. 
Recently, Barrionuevo et al2 and Kuo et aI3 detected 
EBV-encoded small nuclear RNA (EBER-1) by in 
situ hybridisation in all the examined extranodal 
NK/T-cell lymphomas (ENKTCL).
NK/T-cell lymphoma arises more frequently in 
Asian countries and central/South America, but is a 
rare entity in North America and Europe, with an 
incidence of less than 1/1 000 000.4
NK/T-cell lymphoma typically presents with 
involvement of the nasal cavity, nasopharynx, 
oropharynx and paranasal sinus as primary sites in 
more than 80% of the cases, referred to as ‘nasal-
type’. Even if most of the patients have the diag-
nosis at stage I/II, there is a high relapse rate after 
radiochemotherapy of more than 30%.5
Extranasal sites include the gastrointestinal 
tract, skin, lung, liver, bone and testis. These 
two subgroups share similar histological and 
immunophenotypic features, expressing CD2, cyto-
plasmic CD3 epsilon, CD56 and TIA-1. Prognosis 
is worse in case of extranasal presentation and poor 
in relapsing and advanced stage patients.
Primary testicular lymphoma (PTL) is defined as 
the testis being the only involved site at presenta-
tion, without other nodal or organ involvement.6 
Diffuse large B-cell lymphoma (DLBCL) constitutes 
more than 70% of testicular lymphomas. Compared 
with DLBCL, testicular ENKTCL is a rare entity 
whether primary or secondary.7
We report here a clinical case of a young patient 
presenting with multiple sinonasal relapses of an 
NK/T-cell lymphoma of the testis. Clinical, radio-
logical presentation and the different modalities of 
treatment are presented.
CaSe preSenTaTion
A 35-year-old Caucasian man was investigated for 
a right testicular mass (measuring 5, 8×5, 3×4, 
5 cm) in October 2015. Classical tumour markers 
for testicular cancer (LDH, APF and HCG) were 
negative. An orchiectomy was performed, and the 
diagnosis of ENKTCL was established. The immu-
nohistochemistry showed a classical positivity for 
CD56, CD3, TIA-1 and EBER; CD5, CD7, CD8 
and TdT were negative and the proliferation index 
was high with Mib-1 at 70%–80%. An initial radio-
logical evaluation with PET-CT and bone marrow 
biopsy were performed that revealed a stage IE 
according to the Ann Arbor classification without 
any other nodal or extranodal localisation. Blood 
EBV PCR was low at 130 cop/mL (the normal 
detection threshold is less than 100 cop/mL). Fibro-
endoscopic examination of the nasal cavity was 
normal without any suspect lesions.
The patient was treated by radiation therapy 
with a total dose of 40 Gy in addition to concom-
itant chemotherapy (weekly cisplatin 30 mg/m²). 
This was followed by three cycles of chemotherapy 
according to the protocol SMILE (ddexametha-
sone, methotrexate, ifosfamide, l-asparaginase and 
etoposide). Radiological examination by a PET-CT 
3 months post-treatment showed a complete remis-
sion of the disease. EBV PCR was still positive with 
389 cop/mL. The patient presented with left-sided 
nasal obstruction 7 months post-treatment without 
any other rhinlogical  symptoms. The fibroendo-
scopic examination of the nasal cavity showed 
a swelling of the mucosa at the level of the nasal 
cavity floor and lateral wall on both sides, predomi-
nating on the left side (figure 1A), with no evidence 
of any exophytic lesion. The CT, MRI and PET-CT 
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imaging (figure 2A,B) showed hypermetabolic activity of the 
nasal cavity on both side highly suggestive for recurrence; there 
was no evidence for testicular relapse and no other suspect nodal 
or extranodal lesion. Deep submucosal biopsies of the nasal 
cavity (figure 1B) confirmed the diagnosis of relapsing NK/T-
cell lymphoma in the nasal cavity. The histological and immu-
nohistochemistry results were similar to the primary disease 
of the right testis. The patient was treated by chemotherapy 
with three cycles according to the protocol GIDOX, (gemcit-
abine, ifosfamide, dexamethasone and oxaliplatin) followed 
by an intensification chemotherapy regimens according to the 
BEAM protocol (BCNU, etoposide, cytarabine and melphalan) 
and autologous stem-cell transplant. Radiological evaluation by 
PET-CT performed at the end of the treatment, showed complete 
response to the treatment without any residual metabolic activity 
or appearance of other suspect lesion (figure 2C). The endo-
scopic examination of the nasal cavity revealed a normal appear-
ance of the mucosa.
Four months later, a routine clinical examination reveals 
a second relapse in the nasal cavity with the same swelling of 
the mucosa, confirmed by a new biopsy. The PET-CT showed 
only a small slightly hypermetabolic cervical node (negative for 
lymphoma on biopsy) (figure 2D). Local radiotherapy (40 Gy) 
of the nasal cavity and the cervical area was performed, followed 
by an allograft. The patient is currently still in remission, 2 years 
after the diagnosis of the first nasal relapse of the NK/T-cell 
lymphoma of the testis.
ouTCome and follow-up
Seven months after the treatment of a stage IE NK/T-cell 
lymphoma of the right testis, the patient presented a nasal 
relapse on the left side without a local recurrence or any other 
organ involvement. This relapse was treated with salvage chemo-
therapy and an autologous stem-cell transplantation.
Radiological and clinical evaluation at the end of the treat-
ment of the nasal relapse showed a complete remission without 
any suspicious hypermetabolic activity on the PET-CT.
A routine follow-up 4 months after this remission showed a 
second nasal relapse on the left side with suspicion of involve-
ment of the cervical lymph node on both sides (slightly hyper-
metabolic but negative for lymphoma at the biopsy) and without 
evidence of recurrence at the level of the testis or any other 
organ involvement. This new relapse was treated with locore-
gional radiotherapy
At 2 years after the diagnosis of the first nasal relapse of the 
NK/T-cell lymphoma, the patient is still in remission.
diSCuSSion
We report the case of a primary extranasal ENKTCL of the testis 
in a young Caucasian man with twice nasal involvement as the 
unique site of relapse. Due to the relapse pattern, we decide to 
describe this case.
Few cases of primary testicular NK/T-cell lymphoma are 
reported in the literature. The largest series has been described 
recently by Huang et al8 who collected 21 new cases in three 
hospitals in China. PTL represents 0.72% of all ENKTCL, 
during the study period. Most of the cases were Asian. Median 
age was 45 years. Seventy-three per cent were diagnosed at stage 
I/II. The 2-year overall survival of patients with de novo testic-
ular NK/T-cell lymphoma was 34%, and the median survival was 
15.3 months, putting forward the aggressiveness of this disease 
and the poor outcome. Even with stages I–II, the 2-year overall 
survival was 43%. In this review, sites of extratesticular involve-
ment and relapse were lymph nodes, skin, contralateral testis, 
bone marrow, spleen, adrenal glands and the central nervous 
system. No nasal cavity was described as a site of relapse in those 
21 cases.
Liang et al9 reported earlier a series of 31 cases of testicular 
NK/T-cell lymphoma with 15 cases of primary and 16 cases of 
non-PTL. In the primary testicular cases, the secondary dissem-
ination sites were the contralateral testis, lymph nodes, skin, 
spleen, central nervous system and liver; the nasopharynx was 
described as a unique site of relapse in only one case. In the 
16 non-primary cases, 5 were secondary to nasal-type NK/T-cell 
lymphoma and 11 had initially multiple organ involvement, 2 of 
which having nasal cavity involvement.
The exact role of autologous stem-cell transplantation remains 
undefined in relapsing disease, however, it seems that our patient 
figure 1 (A) Endoscopic view shows a swelling of the mucosa of 
the nasal cavity on the left side without any exophytic lesion. (B) 
Deep submucosal biopsy of the nasal cavity on the left side shows an 
Important infiltration of tumorous tissues.
figure 2 (A) CT showed complete opacity of the nasal cavity on both 
sides without any bony erosion. (B) PET-scan showed hypermetabolic 
activity on both sides of the nasal cavity (SUV 8, 9), suspicious of 
relapsing testicular lymphoma. (C) PET-scan after the treatment 
of the first nasal relapse showed complete remission without any 
residual suspicious hypermetabolic activity. (D) PET-scan performed 
4 months after the end of the treatment of the nasal relapse showed 
hypermetabolic activity (SUV 6, 5) in the nasal cavity on the left 
side, highly suspicious of a second nasal relapse of the NK/T-cell 
lymphoma. NK, natural killer.
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was in complete remission after salvage therapy. We, therefore, 
decided to add the stem-cell transplantation in order to offer 
him the maximum chance of durable response.
The prognosis of primary NK/T-cell lymphoma of the testis 
remains very poor and, even more so, in the nasal type. In a series 
of 101 patients of ENKTCL in Taiwan, published by Su et al,5 
5 years overall survival was 55% and 72% in patients with stages 
I–II. EBV DNA is a surrogate biomarker of the lymphoma load 
and should be followed during the course of the disease.10
The two relapses in the nasal cavity in our patient raise ques-
tions as to the advanced stage of a primary nasal ENKTCL with 
infraclinical involvement of the nasal cavity, since deep biop-
sies were not undertaken initially. However, this case and those 
described in the series mentioned above showed the need to treat 
these patients very aggressively, similarly to advanced stages, 
with polychemotherapy-containing l-asparaginase, very active in 
this disease and high doses of methotrexate due to the high risk 
of brain relapse.11 New treatment and new multimodal strategies 
of treatment should be investigated.
learning points
 ► Nasal relapse of a primary isolated natural killer (NK)/T-cell 
lymphoma of the testis is described for the first time, along 
with its presentation and applied treatment.
 ► Extranasal NK/T-cell lymphoma is a very rare clinical entity in 
Western countries and is always associated with the Epstein-
Barr virus.
 ► Despite multimodal therapies, the prognosis is poor with very 
low survival rates.
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